SCHEMBL3850328

SCHEMBL3850328

O=C(O)CCCN1C(=O)c2cccc3cc(C(=O)O)cc(c23)C1=O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.76
KMT2A Q03164 4/20 0.76
KDM4E B2RXH2 4/20 0.59
SMN1; SMN2 Q16637 1/20 0.56
ALDH1A1 P00352 5/20 0.53
LMNA P02545 1/20 0.53
POLB P06746 1/20 0.53
LPAR2 Q9HBW0 2/20 0.53
MAPT P10636 3/20 0.51
CYP1A2 P05177 2/20 0.51
HPGD P15428 2/20 0.51
HSD17B10 Q99714 2/20 0.51
AKR1B1 P15121 1/20 0.51
ALOX15 P16050 1/20 0.51
HDAC3 O15379 1/20 0.51
LTA4H P09960 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC2 Q92769 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3849346 0.90 MEN1 (0.72) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL3134908 0.87 MEN1 (1.00) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL3850365 0.85 MEN1 (0.76) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL13742157 0.83 MEN1 (0.76) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4143779 0.82 MEN1 (0.59) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL3857027 0.82 MEN1 (0.70) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL3851738 0.82 MEN1 (0.70) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL10018574 0.81 KMT2A (0.89) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL3853314 0.81 MEN1 (0.69) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL3856200 0.81 MEN1 (0.69) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579468-B2 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2009-08-25 US claimed
EP-1931637-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2008-06-18 EP claimed
US-20070093474-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-04-26 US claimed
WO-2007030940-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO claimed
US-7579468-B2 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2009-08-25 US disclosed
US-7579468-B2 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2009-08-25 US disclosed
US-7579468-B2 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2009-08-25 US disclosed
US-20070093474-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-04-26 US disclosed
US-20070093474-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-04-26 US disclosed
US-20070093474-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-04-26 US disclosed
WO-2007030940-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093474-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 MEN1 3865/4885KMT2A 4267/4885KDM4E 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.